| Title | Antiretroviral management of treatment-naive patients. | | Author(s) | Gulick RM | | Institution | Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, 525 East 68th Street, Box 566, New York, NY 10021, USA. | | Source | Infect Dis Clin North Am 2007 Mar; 21(1):71-84. | | Abstract | Antiretroviral management of treatment-naive patients begins with the decision of when to start treatment. Current treatment guidelines suggest starting therapy in anyone with AIDS, HIV-related symptoms, or a CD4 cell count less than 200/mm(3) regardless of symptoms. Starting treatment in asymptomatic patients with CD4 of more than 200 requires consideration of a number of pros and cons, and individualization is the key. Recommended first-line antiretroviral regimens consist of two nucleoside reverse transcriptase inhibitors together with either a nonnucleoside reverse transcriptase inhibitor or a protease inhibitor (with or without ritonavir boosting). The goal of antiretroviral therapy is maximally to suppress viremia, enhance or improve immune function, and prevent clinical progression. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 17502230 |
|
